AstraZeneca discontinues eVOLVE-Lung02 Phase 3 trial for futility
AZN is discontinuing the eVOLVE-Lung02 Phase 3 trial after the IDMC concluded it was unlikely to meet either dual primary endpoint.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.